Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Inozyme Pharma Raises $67M In Series A2 Financing To Develop Therapies For Rare Mineralization Disorders
Venture Capital

Inozyme Pharma Raises $67M In Series A2 Financing To Develop Therapies For Rare Mineralization Disorders

by vcaonline.com posted 4months ago 126 views
Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders – Financing to Advance Lead Development Program, INZ-701, through Clinical Proof of Concept in Two Indications – – Company Expands Pipeline with New Program for a Rare Mineralization Disorder – BOSTON, April 10, 2019-- Inozyme Pharma, Inc., a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, today announced that the Company raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments.

In this article